<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696904</url>
  </required_header>
  <id_info>
    <org_study_id>M10-351</org_study_id>
    <nct_id>NCT00696904</nct_id>
  </id_info>
  <brief_title>Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333
      in healthy volunteers and the antiviral activity in HCV infected subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, double-blind, randomized, placebo-controlled clinical trial in healthy and HCV
      genotype 1 infected adults to evaluate safety, tolerability, antiviral activity and
      pharmacokinetics of ABT-333.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of pharmacokinetic variables and mean change in HCV RNA level from baseline.</measure>
    <time_frame>approximately 1 week or less</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of safety measures, including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.</measure>
    <time_frame>approximately 1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of variance of pharmacokinetic variables for subjects fasting or nonfasting.</measure>
    <time_frame>approximately 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>Capsule, see arms for intervention description</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, see arms for intervention description</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Main Selection Criteria for Healthy Volunteers:

               -  Subject has provided written consent.

               -  Subject is in general good health.

               -  If female, subject is postmenopausal.

               -  If female, subject is not pregnant and is not breast-feeding.

          -  Main Selection Criteria for HCV+ Subjects:

               -  Subject is HAV-IgM, HBsAg or HIV Ab negative.

               -  Subject is HCV genotype 1 with HCV RNA of &gt; 50,000 IU/mL.

               -  Subject is excluded if they have previously received antiviral therapy for HCV
                  infection

               -  Subjects must demonstrate chronic hepatitis C infection for at least 6 months
                  prior to study enrollment

               -  Subjects must have a prior liver biopsy with histology consistent with HCV
                  induced liver damage, and with no evidence of cirrhosis or liver pathology due
                  to any cause other than chronic HCV.

        Exclusion Criteria:

        See above for main selection criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Global Medical Information</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <lastchanged_date>October 19, 2010</lastchanged_date>
  <firstreceived_date>June 11, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Daniel Cohen, MD, Study Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
